<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04330872</url>
  </required_header>
  <id_info>
    <org_study_id>01-18-156</org_study_id>
    <nct_id>NCT04330872</nct_id>
  </id_info>
  <brief_title>An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke.</brief_title>
  <acronym>ECASIS</acronym>
  <official_title>An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke. Non-randomized Interventional Controlled Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamad Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hamad Medical Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uncertainty remains regarding the impact of enteric-coated (EC) aspirin as it relates to the
      reduction of CV risk. We hypothesize that EC formulation based on the previous report may
      blunt aspirin response as evidenced by reduced Thromboxane A2 (TXA 2) levels in diabetic
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 26, 2019</start_date>
  <completion_date type="Actual">March 4, 2020</completion_date>
  <primary_completion_date type="Actual">January 4, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Aspirin non-responders.</measure>
    <time_frame>At &quot;Day 3&quot;</time_frame>
    <description>Aspirin nonresponsiveness is defined as a level of residual serum TXB2 associated with elevated thrombotic risk (&lt;99.0% inhibition or TXB2 &gt;3.1 ng/ml) after 3 daily aspirin doses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Gastrointestinal bleeding consequent upon aspirin therapy.</measure>
    <time_frame>After three daily aspirin doses ( at &quot;Day 3&quot;)</time_frame>
    <description>Major and minor GIT bleeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Stroke, Ischemic</condition>
  <arm_group>
    <arm_group_label>Enteric coated Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EC aspirin loading dose 300mg followed by 100 mg (2 days).
The study's total duration is 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plain Aspirin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dispersible Aspirin loading dose 300mg followed by 75mg tablets (2 days)
The study's total duration is 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enteric Coated Aspirin Tablet</intervention_name>
    <description>Study participants will be assigned to receive either EC Aspirin and will be required to continue taking them throughout the study (three days).</description>
    <arm_group_label>Enteric coated Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plain Aspirin</intervention_name>
    <description>Study participants will be assigned to receive either Plain Aspirin and will be required to continue taking them throughout the study (three days).</description>
    <arm_group_label>Plain Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Newly diagnosed ischemic stroke who are just about to start aspirin.

          2. No prior history of cardiovascular morbidity (including ischemic heart disease,
             chronic kidney disease, peripheral vascular disease) 3-18- 75 years.

        4-Patients with ischemic stroke who underwent reperfusion intervention (catheter-directed
        thrombolysis and/or thrombectomy) regardless of the time of presentation (i.e within or
        outside the therapeutic window as the managing stroke deem fit.

        Exclusion Criteria:

          1. Concomitant antiplatelet therapy (irrespective of the duration of the treatment).

          2. Patients on any prostaglandins related medications (non-steroidal anti-inflammatory
             drugs, misoprostol, and other ant secretory drugs among others).

          3. Any salicylate-containing supplements.

          4. Patients on the NG tube will be excluded from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hamad Medical Corporation</name>
      <address>
        <city>Doha</city>
        <zip>3050</zip>
        <country>Qatar</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Qatar</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

